• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » IMS Health advances cloud-based social media analytics with acquisition of Semantelli

IMS Health advances cloud-based social media analytics with acquisition of Semantelli

May 1, 2013
CenterWatch Staff

IMS Health, a provider of information, services and technology for the healthcare industry, has acquired Semantelli, a Bridgewater, N.J.-based social media analytics company, to extend its marketing and consumer engagement capabilities for healthcare organizations around the world.

Semantelli offers clients a robust set of cloud-based tools that automate the collection of healthcare-specific social media content, providing real-time monitoring for reputation and opportunity management and delivering extensive insights into consumer and physician behavior and sentiments.

Semantelli will become part of IMS's innovative suite of social media solutions that support healthcare organizations in the areas of market assessment, competitive intelligence, brand performance, risk management and consumer/healthcare professional engagement. This addition complements IMS's advanced business intelligence and marketing solutions, and the company's ability to integrate its industry-leading healthcare information with social media content to drive improved business performance. Building on Semantelli's responsible use of information, IMS will apply its global expertise in privacy-enhancing technologies, methodologies and practices to advance strong data protection, patient privacy and accountability.

"This acquisition marks an important step in expanding IMS's capabilities in the social media management and analytics space, where there is accelerating demand for solutions that help clients take advantage of new channels to connect more actively with healthcare professionals and consumers," said Stefan Linn, senior vice president of strategy and global pharmaceutical solutions, IMS Health. "Social media has become an integral part of the healthcare experience, and navigating this channel effectively to unlock the right information for making decisions is critical. The combination of Semantelli's technology and IMS's healthcare data and privacy management expertise will fuel ongoing innovation in a responsible manner, enabling our clients to identify vital trends and take actions on real-world insights in real time."

Semantelli's proprietary technologies enable organizations to access, navigate and analyze both structured and unstructured data from thousands of online resources, including popular social networks and other social media platforms. The company's global web 3.0 platform supports more than 50 languages and leverages a comprehensive set of medical taxonomies and algorithms, as well as state-of-the-art Named Entity Recognition, Natural Language Processing and Machine Learning, to detect trends in disease areas and treatments. In addition, insights on healthcare professionals can be integrated into traditional customer relationship management (CRM) systems, making it easier for clients to get greater value from their commercial data.

"Life sciences companies, payers and providers need a fast and effective way to gain actionable insights from social media platforms,” said Siva Nadarajah, CEO of Semantelli. “As part of IMS, we can bring the quickest and most accurate access to these insights to help manage risks, grow brand awareness, generate leads and identify emerging trends. This combination will accelerate the development of comprehensive, integrated solutions that enhance value to clients.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing